Vaccine antigen HBsAg

Hepatitis B vaccine is manufactured using recombinant DNA technology to express hepatitis B surface antigen (HBsAg) in yeast. This is further purified with biochemical separation techniques to produce the vaccine. The vaccines are formulated to contain 10 to 40 meg of HBsAg protein/mL. Hepatitis B vaccine is available as a single component or in combination vaccines. 

Hepatitis B surface antigen (HBsAg) Tobacco leaf Mice vaccinated parenterally produced all IgG subclasses and IgM. - 3,56... 

Engerix B (tradename) is a subunit vaccine containing purified recombinant hepatitis B surface antigen (HBsAg) that gained approval in the USA in 1998. It is indicated for active immunization against infection caused by all known serotypes of hepatitis B virus. 

Hepatitis B vaccine Suspension of hepatitis B surface antigen (HBsAg) purified from the plasma of hepatitis B sufferers Active immunization against hepatitis B (note this preparation has largely been superseded by HBsAg preparations produced by genetic engineering)... 

Plant cell culture has been used extensively for the production of biopharmaceuticals. A few examples are illustrated here, and a more extensive list can be found in Table 6.4. Smith et al. (2002) employed both soybean and tobacco cell lines to produce a hepatitis virus surface antigen (HBsAg), to be used as a vaccine, in shaker flask cultures. The authors found that the titers of HBsAg in soybean cell culture were 65 pg/g fresh weight, and 10-fold lower in tobacco cell culture, resulting in productivities of 1 mg/L/d and 0.16 mg/L/d, respectively. These numbers correspond well with those found for yeast batch cultures (1.5 mg/L/d). 

Fig. 24.11 Production of hepatitis B subunit vaccine. The gene for the hepatitis B surface antigen (HBsAg) was isolated from a...

Few new data on hepatitis B infection are available and thus are not presented here. Prevalence of total anti-bodies is not a satisfactory measure as it reflects vaccination as well as past, current or chronic infection. However, numbers of injectors with no hepatitis B antibodies indicate a population at risk who would benefit from vaccination. Those who remain infectious can be identified using a specific serological marker (hepatitis B surface antigen HBsAg). Data on levels of HBsAg will be included in future annual reports. 

One of the most successful preparations to date is that of an edible vaccine for hepatitis B.66 Volunteers who had been previously immunized parenterally (by injection, not by mouth) with the licensed, recombinant hepatitis B vaccine in yeast were given three doses over a period of 28 days of the hepatitis B antigen (HBsAg) as a recombinant protein in potatoes. The doses consisted of 100 to 110 grams of the potato that were ingested by the volunteers. Nine of the 17 volunteers responded with significant antibody production over those values measured before they ingested the potatoes. The serum... 

The improved efficacy of liposome-associated adjuvants has been observed with hepatitis B surface antigen (HbsAg) incorporated in negatively charged liposomes. The synthetic peptides of T- and B-cell epitopes in HbsAg have been used in the development of the HBV vaccine by incorporating poorly immunogenic peptides in lipid A. 

---